These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14592495)

  • 1. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).
    Wityak J; Das J; Moquin RV; Shen Z; Lin J; Chen P; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; Schieven GL; Kanner SB; Barrish JC
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4007-10. PubMed ID: 14592495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56(lck) inhibitors.
    Das J; Moquin RV; Lin J; Liu C; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC; Wityak J
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2587-90. PubMed ID: 12852972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117.
    Das J; Lin J; Moquin RV; Shen Z; Spergel SH; Wityak J; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2003 Jul; 13(13):2145-9. PubMed ID: 12798323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
    Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck).
    Chen P; Norris D; Iwanowicz EJ; Spergel SH; Lin J; Gu HH; Shen Z; Wityak J; Lin TA; Pang S; De Fex HF; Pitt S; Shen DR; Doweyko AM; Bassolino DA; Roberge JY; Poss MA; Chen BC; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2002 May; 12(10):1361-4. PubMed ID: 11992777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
    Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
    Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domain.
    Hobbs CJ; Bit RA; Cansfield AD; Harris B; Hill CH; Hilyard KL; Kilford IR; Kitas E; Kroehn A; Lovell P; Pole D; Rugman P; Sherborne BS; Smith IE; Vesey DR; Walmsley DL; Whittaker D; Williams G; Wilson F; Banner D; Surgenor A; Borkakoti N
    Bioorg Med Chem Lett; 2002 May; 12(10):1365-9. PubMed ID: 11992778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
    Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
    Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II.
    Burchat AF; Calderwood DJ; Hirst GC; Holman NJ; Johnston DN; Munschauer R; Rafferty P; Tometzki GB
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2171-4. PubMed ID: 11012022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of thienopyridines as Src-family selective Lck inhibitors.
    Abbott L; Betschmann P; Burchat A; Calderwood DJ; Davis H; Hrnciar P; Hirst GC; Li B; Morytko M; Mullen K; Yang B
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1167-71. PubMed ID: 17234410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
    Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
    J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.
    Arnold LD; Calderwood DJ; Dixon RW; Johnston DN; Kamens JS; Munschauer R; Rafferty P; Ratnofsky SE
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2167-70. PubMed ID: 11012021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
    Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency.
    Chen P; Iwanowicz EJ; Norris D; Gu HH; Lin J; Moquin RV; Das J; Wityak J; Spergel SH; de Fex H; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3153-6. PubMed ID: 12372522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validated quantitative structure-activity relationship analysis of a series of 2-aminothiazole based p56(Lck) inhibitors.
    Li J; Du J; Xi L; Liu H; Yao X; Liu M
    Anal Chim Acta; 2009 Jan; 631(1):29-39. PubMed ID: 19046675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011-2021) focussing on structure-activity relationship (SAR) and docking insights.
    Elkamhawy A; Ali EMH; Lee K
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1574-1602. PubMed ID: 34233563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.